Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency.

What Was Tested

The paper reports a study of Vitamin D, published as a controlled clinical trial.

The researchers investigated this effect in adults and its clinical relevance in the management of GH deficiency (GHD).

Who Took Part

The abstract describes 39 subjects taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

The frequency of IGF1 values ≥50th age- and sex-specific percentile in relation to vitamin D status, as determined by the concentration of 25-hydroxyvitamin D (25(OH)D), was retrospectively assessed in 69 GHD patients (57.4±16.6 years) on stable hormone replacement and with 25(OH)D and IGF1 concurrently measured.

What Was Measured

PubMed files the paper under topics including Hormone Replacement Therapy, Human Growth Hormone, Insulin-Like Growth Factor I, Italy, Linear Models, Logistic Models and Medical Records.

What This Means in Plain Language

This is a controlled clinical trial of Vitamin D in 39 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2013 (European journal of endocrinology), a journal based in England.

More context: all human trials.